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Considering the various pharmacological activities of epigallocatechin-3-O-gallate (EGCG) including anticancer, and anti-
inflammatory, antidiabetic, and so forth, relatively less attention has been paid to the antiaging eﬀect of EGCG on primary cells.
In this study, the preventive eﬀects of EGCG against serial passage-induced senescence were investigated in primary cells including
rat vascular smooth muscle cells (RVSMCs), human dermal fibroblasts (HDFs), and human articular chondrocytes (HACs). The
involvement of Sirt1 and acetylated p53 was examined as an underlying mechanism for the senescence preventive activity of EGCG
in HDFs. All cells were employed with the initial passage number (PN) between 3 and 7. For inducing senescence, the cells were
serially passaged at the predetermined times and intervals in the absence or presence of EGCG (50 or 100 μM). Serial passage-
induced senescence in RVSMCs and HACs was able to be significantly prevented at 50 μM EGCG, while in HDFs, 100 μM EGCG
could significantly prevent senescence and recover their cell cycle progression close to the normal level. Furthermore, EGCG was
found to prevent serial passage- and H2O2-induced senescence in HDFs by suppressing p53 acetylation, but the Sirt1 activity was
unaﬀected. In addition, proliferating HDFs showed similar cellular uptake of FITC-conjugated EGCG into the cytoplasm with
their senescent counterparts but diﬀerent nuclear translocation of it from them, which would partly account for the diﬀerential
responses to EGCG in proliferating versus senescent cells. Taking these results into consideration, it is suggested that EGCG may
be exploited to craft strategies for the development of an antiaging or age-delaying agent.
1. Introduction
Cellular senescencemeans a state of irreversible growth arrest
by which normal cells lose the ability to divide generally
after about 50 cell divisions in vitro [1]. Some cells become
senescent after fewer replication cycles as a result of DNA
double-strand breaks. This phenomenon, also known as
replicative senescence, was first reported by Hayflick and
Moorhead observing that normal human fibroblasts were
able to enter a state of irreversible growth arrest after serial
cultivation in vitro; meanwhile cancer cells did not enter
this growth arrest state and proliferated indefinitely [1].
Cellular senescence can be triggered by multiple mechanisms
including telomere shortening, the epigenetic derepression
of the cyclin-dependent kinase (CDK) inhibitor 2A locus,
and DNA damage [2]. Moreover, these mechanisms limit
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excessive or aberrant cellular proliferation, and so the state of
senescence protects against the development of cancer and is
involved in aging [2]. During the last decade, much evidence
suggests that resveratrol, a polyphenol found in red wine,
exerts a calorie restriction mimetic activity with a potential
antiaging property by activating silent information regulator
(SIR) genes (sirtuins) or inhibiting cAMP-degrading phos-
phodiesterases [3–6].
From this point of view, our attention has been paid
to epigallocatechin3-O-gallate (EGCG), since it has a very
similar structure to that of resveratrol including hydroxyls in
the two metapositions of the A ring, trans to the B ring with
a 4′ or 3′, 4′ hydroxyl pattern [6]. EGCG, the most active
and major component of polyphenols in green tea, is well
known to be a primary contributor to the potential benefits
of green tea to human health [7–9]. But the role of EGCG in
the etiology and treatment of aging-related diseases, includ-
ing neurodegeneration, carcinogenesis, atherosclerosis and
obesity is hardly definitive, and some have still challenged
the very nature of its action mechanism within the body
[10, 11]. Although the mechanism of action is disputed
by certain investigators, there remains a clear recognition
based on many in vitro, in vivo, and epidemiologic studies
suggesting that EGCG possesses beneficial health eﬀects
[12, 13]. The main action mechanisms of EGCG have
been suggested as being involved in its potent antioxidant
activity, which allows neuroprotection and cardioprotection
[14, 15]. Other favored mechanisms entail chemopreventive,
anti-inflammatory, antithrombotic, and even cytoprotective
eﬀects of EGCG [16–18]. In the present study, we investi-
gated the preventive eﬀects of EGCG against serial passage-
andH2O2-induced senescence in primary cells. As a potential
mechanism for this senescence preventive activity of EGCG,
we determined the involvement of Sirt1 and acetylated p53
expression. In addition, we examined diﬀerential responses
to EGCG in proliferating versus senescent primary cells by
comparing the incorporation pattern of EGCG conjugated
with fluorescein-4-isothiocyanate (FITC) in proliferating
fibroblasts with that in their senescent counterparts.
2. Materials andMethods
2.1. Cell Culture and Conditions. Rat vascular smoothmuscle
cells (RVSMCs) were isolated by limited enzymatic digestion
from the tunica media of thoracic aorta of male young adult
(10wk old) Wistar rats (280 ∼ 300 g in weight, Shimizu
Laboratory Supplies, Kyoto, Japan) as previously reported
[19]. The primarily cultured RVSMCs were maintained
in Dulbecco’s modified Eagle’s medium (DMEM, Sigma-
Aldrich Co., St. Louis, MO, USA) supplemented with
10% fetal bovine serum (FBS, Sigma-Aldrich Co.) and
1% antibiotic antimycotic solution (including 10,000 units
penicillin, 10mg streptomycin, and 25 μg amphotericin B
per mL, Sigma-Aldrich Co.) at 37◦C in 95% humidity and
5% CO2. Studies were performed with the cells third to
fifth passage. Human articular chondrocytes (HACs) were
kindly supported from Dr. J. Y. Bae (Institute for Frontier
Medical Sciences, Kyoto University, Japan) and subcultured
in DMEM/HAM’s F-12 (Sigma-Aldrich Co.) supplemented
with 10% FBS (Sigma-Aldrich Co.) and 1% antibiotic-
antimycotic solution under the same conditions as reported
elsewhere [20]. HACs below fifth passage were plated prior
to the usage. Human dermal fibroblasts (HDFs) were kindly
supported from Professor D. K. Rah (Department of Plastic
and Reconstructive Surgery, Yonsei University College of
Medicine, Seoul, Korea) and routinely maintained in a
complete DMEM under the same conditions as previously
reported [21]. Studies were performed within the initial
passage number (PN) of 5 ∼ 7.
2.2. Cytotoxicity Assay. EGCG (MW 458.4) was kindly
supported from BMG Inc. (Kyoto, Japan). The number
of viable cells was indirectly quantified using highly
water-soluble tetrazolium salt [WST-8, 2-(2-methoxy-4-
nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-
tetrazolium, monosodium salt] (Dojindo Lab., Kumamoto,
Japan) reduced to a water-soluble formazan dye by
mitochondrial dehydrogenases. The cell viability is well
known to be directly proportional to the metabolic
reaction products obtained in WST-8. After grown to 80%
confluence, all primary cells (RVSMCs, HDFs, and HACs)
were treated with increasing concentrations (0 ∼ 2, 000μM)
of EGCG and then incubated with WST-8 for the last 4 hrs
of the culture period (24 h) at 37◦C in the dark. In order
to avoid a direct reaction between antioxidant, EGCG and
WST-8 to be reduced, the excess EGCG, was completely
removed, and the medium was exchanged before adding
WST-8. Parallel sets of wells containing freshly cultured
nontreated cells were regarded as negative (−) controls.
The absorbance was determined at 450 nm using an ELISA
reader (SpectraMax 340, Molecular Device Co., Sunnyvale,
CA, USA). The relative cell viability was determined as
the percentage ratio of the optical density in the medium
(containing EGCG at each concentration) to that in the fresh
control medium. The IC50 value, the concentration (%)
inhibiting the growth of cells by 50%, was estimated from
the relative cell viability profile.
2.3. Senescence Induction by Serial Passage and EGCG Treat-
ment. For inducing senescence, primary cells were serially
passaged at the predetermined number of times and intervals
in the absence or presence of EGCG [22]. All cells were plated
into 48-well plates with the initial seeding number of 2× 104
cells/mL and grown to 80% confluence by incubation for
48 h. Every passage was followed by cultivation for 24 h in
a CO2 incubator with media refreshment. From passage 3 to
20, EGCG was added to the culture media of RVSMCs and
HACs every time at 50 μM with media refreshment during
serial culture. HDFs were subcultured serially from passage
7 to ≥40 in the presence of EGCG (50 and 100 μM). The
concentration of EGCG, which exerted no adverse eﬀects
on the viability of each primary cell, was determined from
each cytotoxicity profile. After serial passage with or without
EGCG treatment, cellular senescence assay, morphological
observation, cell cycle analysis, and western blot analysis were
performed as described below in details.
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2.4. Cellular Senescence Assay. To compare the senescence
levels of serially passaged primary cells treated with or
without EGCG, the activity of senescence-associated β-
galactosidase (SABG), a marker of cellular senescence, was
determined by using a cellular senescence assay kit (Chemi-
con International Inc., Temecula, CA, USA) according to
the manufacturer’s instructions. After aspirating the growth
media, the cells were washed once with 2mL phosphate-
buﬀered saline (PBS, pH 7.0), added to 1mL 1X fixing
solution per well and incubated at room temperature for
10 ∼ 15min. After removal of the fixing solution, the
cells were washed again with 2mL PBS. Then 2mL of
freshly prepared 1X SABG detection solution was added,
and the mixture was incubated at 37◦C without CO2 and
protected from the light for at least 4 h. The blue stained cells
were counted under an Olympus IX70 inverted microscope
(Olympus Optical Co., Osaka, Japan), and the number of
senescent cells per mm2 was graphed.
2.5. Cell Cycle Analysis. For cell cycle analysis, each cell,
following serial passage in the absence or presence of EGCG,
was collected by trypsinization and washed with cold PBS
(pH 7.2). The cells were resuspended in 95% cold methanol
for 1 h at 4◦C and then centrifuged at 120×g for 5min.
The resultant pellet was washed twice with cold PBS and
incubated with RNase A (at 20 units/mL final concentration,
Sigma-Aldrich Co.) at 37◦C for 30min. Intracellular DNA
was labeled with 100 μg/mL propidium iodide (PI, Sigma-
Aldrich Co.) for 1 h. At least 20,000 cells were counted by
a flow cytometer (FACSCalibur, BD Biosciences, San Jose,
CA, USA), and the data obtained were with the ModFit
LT program for Mac version 3.0 software (Verity Software
House, Topsham, ME, USA).
2.6. Western Blot Analysis. After serial passage and H2O2
addition at 150 μM for 1 h, in the absence or presence of
EGCG, HDFs were washed twice with cold PBS (10mM, pH
7.4). Ice-cold RIPA lysis buﬀer (Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA) was added to the cells for
5min. The cells were scraped, and the lysate was cleared by
centrifugation at 14,000×g for 20min at 4◦C. Proteins were
extracted from the total lysate, and the protein concentration
was determined by a BCATM protein assay according to
the manufacturer’s protocol (Pierce, Rockford, IL, USA).
For immunoblot analysis, 35–40 μg of protein was run on
a 4/20 polyacrylamide-SDS gel (Daiichi Pure Chemicals
Co., Ltd., Tokyo, Japan) for 1 h at 30mA and blotted to a
PVDF membrane for 50min at 35mA. The membrane was
blocked in a blocking buﬀer (Nacalai Tesque Inc., Kyoto,
Japan) for 1 h at room temperature and then incubated with
primary antibody (Ab). The membrane was treated with
either an antimouse IgG (1:2,000, Amersham Biosciences,
Buckinghamshire, UK) or an antirabbit IgG secondary
Ab (1:5,000, Santa Cruz Biotechnology Inc.), horseradish
peroxidase-conjugated. Protein expression was detected by a
Chemilumi-one chemiluminescent kit (Nacalai Tesque Inc.)
and X-ray film (Fujifilm, Tokyo, Japan). Densitometric anal-
yses were performed with a Scion image (Scion Corporation,
Frederick, MD, USA). Immunoblotting was performed using
Abs directed against the following antigens: Sirt1 (mouse
monoclonal IgG1) and acetyl-p53 (rabbit polyclonal Ab)
used in a 1:500–1,000 dilution from Upstate Biotechnology
Inc. (Lake Placid, NY, USA), p53 (rabbit polyclonal Ab)
and p21 (rabbit monoclonal Ab) at 1 : 500 dilution from
Cell Signaling Technology Inc. (Danvers, MA, USA), and
as the reference, glyceraldehyde-3-phosphate dehydrogenase
(GAPDH, mouse monoclonal Ab) at 1 : 5,000 dilution from
Chemicon International Inc.
2.7. Cellular Uptake of FITC-EGCG in HDFs. In order to
examine the diﬀerential incorporation patterns of EGCG
into the proliferating HDFs (with 5 PN) and their senescent
counterparts (with 30 PN), EGCG was conjugated with FITC
(Dojindo Lab., Kumamoto, Japan) by using the same pro-
cedures as reported elsewhere [23]. When the cells reached
80% confluence, they were treated with 100 μM FITC-EGCG
for 8 h and then fixed with 3.5% paraformaldehyde in 0.1M
phosphate buﬀer (pH 7.0) for 5min at room temperature.
Afterwards, the cellular uptake of FITC-EGCGwas examined
with a fluorescence microscope (Biozero-8000, Keyence,
Osaka, Japan) and a confocal laser scanning microscope
(LSM 510, Carl Zeiss Advanced Imaging Microscopy, Jena,
Germany).
2.8. Statistical Analysis. All variables were tested in three
independent cultures for each experiment, which was
repeated twice (n = 6). The results are reported as a
mean± standard deviation (SD) compared with the non-
treated controls. A one-way analysis of variance (ANOVA,
SAS Institute Inc., Cary, NC, USA), which was followed by
a Tukey honestly significant diﬀerence (HSD) test for the
multiple comparisons, was used to detect the senescence
level and cell cycle progression of serially passaged primary
cells before and after EGCG treatment and eﬀects of EGCG
on Sirt1, acetyl-p53, p53, and/or p21 expression in serially
passaged and H2O2-treated HDFs. The P value < 0.05 was
considered statistically significant.
3. Results and Discussion
3.1. Cytotoxicity of EGCG to Proliferating and Senescent Cells.
Cytotoxicity of EGCG to proliferating and senescent primary
cells was determined by WST-8 assay as shown in Table 1.
Proliferating (PN 3) RVSMCs and their senescent (PN 20)
counterparts exposed to EGCG for 24 h showed a dose-
dependent decrease in the relative cell viability (data not
shown) with the IC50 values of about 1,100 and 1,155 μM,
respectively. In proliferating and senescent HACs treated
with the concentrations of EGCG up to 2,000 μM, the IC50
values were shown to be approximately 320 and 327 μM,
respectively. The IC50 values of EGCG were determined
as 620 and 631 μM for proliferating and senescent HDFs,
respectively. Other study revealed that IC50 values of EGCG
were 78.0 and 84.4 μM for young and old human diploid
fibroblasts, respectively [24]. Those values were about four
times lower than our results. There are a number of
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Table 1: IC50 values of EGCG to proliferating and senescent
primary cells.
Primary cells IC50 of EGCG, μM (μg/mL)
Proliferating RVSMCs 1100 (≈500)
Senescent RVSMCs 1155 (≈529)
Proliferating HACs 320 (≈147)
Senescent HACs 327 (≈150)
Proliferating HDFs 620 (≈284)
Senescent HDFs 631 (≈289)
explanations for this inconsistency, including diﬀerence in
cell source (IMR-90 from human lung), the method (Alamar
blue staining) for determining cell viability, EGCG treatment
period (7 d), and senescent levels of young (population
doubling levels of 25 ∼ 30) and old (population doubling
levels of >45) cells. From these results, it was found that
RVSMCs were the least sensitive to EGCG among the
primary cells employed in this study. This result implies that
the cellular response and sensitivity to EGCG were diﬀerent
according to the cell species and tissue origin, which resulted
in the variation of the IC50 value of EGCG to the primary
cells, namely, the diﬀerential cytotoxicity exerted by EGCG.
3.2. Senescence Level of Serially Passaged Primary Cells
before and after EGCG Treatment. Cellular senescence is the
phenomenon, where cell division rate slows or ceases with
the cells becoming unresponsive to mitogenic stimuli but
remaining viable for extended periods of time [25]. Upon
entering the state of senescence, cells undergo a dramatic
change in morphology—their volume increases and they
lose their original shape, acquiring a flattened cytoplasm
[25]. For inducing senescence here, RVSMCs and HACs
with the initial PN below 5 were serially passaged at the
predetermined times and intervals in the absence or presence
of 50 μM EGCG. After serial passage, SABG assay and
optical microscopy were performed in order to compare the
senescence levels and morphologies of the cells, respectively,
treated with and without EGCG (Figure 1). RVSMCs and
HACs stained with SABG were less readily detected at early
passage with a small degree of changes in their size and
morphology (Figures 1(a) and 1(b)). However, most of
nontreated cells were stained blue after serial subculture
(at 20 passages). On the other hand, when the cells were
treated with 50 μM EGCG, the number of cells stained with
SABG was very small or undetected. The quantitative results
revealed that serial passage-induced senescence in RVSMCs
and HACs was significantly (P < 0.05) prevented by 50 μM
EGCG treatment (Figures 1(c) and 1(d)).
In the case of HDFs with the initial PN between 5
and 7, the cells before senescence exhibited spindle-shaped
morphology, whereas after serial passages they grew larger,
flattened shape and expressed blue spots showing lipo-
fuscin accumulation (Figure 2(a)). Serial passage-induced
senescence in HDFs was partly prevented at 50 μM EGCG,
while 100 μM EGCG significantly (P < 0.05) prevented
cellular senescence (Figure 2(b)). A seminal report demon-
strated that the aging level of human dermal microvascular
endothelial cells with 20 PN noticeably decreased by the
treatment with antiaging agents such as kinetin, EGCG, all-
trans retinoic acid, and selenium;meanwhile the proliferative
and metabolic activity significantly increased [26].
3.3. Cell Cycle Progression in Serially Passaged Primary Cells
before and after EGCG Treatment. To quantify cell cycle
progression, the DNA content was analyzed by FACS with
PI staining (Table 2). In RVSMCs at late passage (20 PN)
without EGCG treatment, 82.1% of the cells had arrested at
the G0/G1 phase with concomitant decrease in the S phase
(Table 2(a)). However, RVSMCs treated with 50 μM EGCG
showed that the cell populations at the G0/G1, S, and G2/M
phases returned to 61.0, 24.4, and 14.6%, respectively, after
serial passage, although they were not the normal levels.
At late passage (30 PN), without or with 50 μM EGCG, the
number of HDFs at the G0/G1 phase significantly (P <
0.05) increased, while the cell population in the S phase
significantly (P < 0.05) decreased (Table 2(b)). Cells that
reach replicative senescence are impaired in their ability
to undergo cell division and are unable to pass the G1/S
restriction point [27]. Accordingly, senescent cells following
serum stimulation can express early and middle G1 genes,
but not late G1 or S phase genes [22]. This inability to traverse
the G1/S barrier results from the inability of senescent cells to
activate complexes of CDK 2 with cyclin E and cyclin D [28].
On the other hand, the treatment with 100 μM EGCG
induced the recovery of cell cycle progression close to the
normal level. In particular, the number of cells arrested at
the G0/G1 phase was significantly (P < 0.05) low in the
cells treated with EGCG at 100 μM. Cyclin D is a protein
that contributes to the early G1 phase and G1/S transition
by binding to CDK4 and CDK6 [19], and its expression
in the cells at late passage treated with kinetin or selenium
was increased as compared to the expression in untreated
cells [26]. Defects in CDK4 and CDK6 activity, caused
by both a decrease in CDK4 protein level and increased
expression of CDK inhibitors p21 and p16, are responsible
for cellular senescence [29]. Accordingly, human fibroblasts
with knocked-out p21 bypass replicative senescence and
become immortalized [30]. The progression of cell cycle
in HACs before and after EGCG treatment showed the
similar pattern to that in HDFs (Table 2(c)). Nevertheless,
precise mechanisms for this eﬀect of EGCG remain not to be
elucidated yet.
3.4. Eﬀects of EGCG on Sirt1 and Acetylated p53 Expression in
Serially Passaged and H2O2-Treated HDFs. The p53, a tumor
suppressor protein, can induce either cell cycle arrest or
apoptosis in response to stress signals such as DNA damage
and reactive oxygen species (ROS) [31]. It has been reported
that p53 acetylation, which promotes cellular senescence, can
be regulated by the Sirt1, the human homolog of yeast SIR2,
a protein that modulates lifespan [32]. It is well established
that reducing food intake (calorie restriction) extends the life
span in a wide range of species [33–35]. The protein involved
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Figure 1: SABG expression of serially passaged RVSMCs (a) and HACs (b) in the absence or presence of 50 μM EGCG. The quantitative
results showed that the RVSMCs (c) and HACs (d) at early passage (PN 3 or 5) that were not treated with EGCG did not stain blue or
only a few stained, but the cells at late passage (PN 20) showed much blue staining of senescent cells. Furthermore, both cells treated with
EGCG showed the number of senescent cells comparable to those with 5 PN. All variables were tested in three independent cultures for each
experiment, which was repeated twice independently (n = 6). The results are reported as a mean± SD and analyzed by a Tukey HSD test.
∗P < 0.05 versus nontreated cells of 3 PN; #P < 0.05 versus nontreated cells of 20 PN.
Table 2: Cell cycle progression in serially passaged RVSMCs (a), HDFs (b), and HACs (c) before and after EGCG treatment.
(a)
RVSMCs
% Cell population
G0/G1 S G2M
Controla 52.5 ± 4.3 35.7 ± 5.1 11.8 ± 3.3
non-treated 82.1 ± 8.2∗ 8.4 ± 2.8∗ 9.5 ± 5.2
EGCG-treated 61.0 ± 4.0∗,# 24.4 ± 4.7∗,# 14.6 ± 4.6
(b)
HDFs
% Cell population
G0/G1 S G2M
Controla 52.2 ± 5.2 31.3 ± 4.2 16.5 ± 3.8
non-treated 78.3 ± 7.1∗ 8.4 ± 3.1∗ 13.3 ± 4.6
50 μM EGCG-treated 69.4 ± 6.0∗,# 15.4 ± 3.6∗,# 15.2 ± 4.9
100 μM EGCG-treated 58.1 ± 5.2# 27.2 ± 6.3# 14.7 ± 5.5
(c)
HACs
% Cell population
G0/G1 S G2M
Controla 71.4 ± 7.1 14.9 ± 5.8 13.7 ± 4.0
non-treated 90.5 ± 8.8∗ 5.1 ± 2.0∗ 4.4 ± 1.5∗
EGCG-treated 75.6 ± 6.5# 11.7 ± 3.5# 12.7 ± 3.4#
(aProliferating cells at early passage (PN 3 or 5)). All variables were tested in three independent cultures for each experiment, which was repeated twice
independently (n = 6). The results are reported as a mean ± SD and analyzed by a Tukey HSD test. ∗P < 0.05 versus control; #P < 0.05 versus non-
treated cells.
in this life span extension is the Sirt1, an enzyme that
belongs to a nicotinamide adenine dinucleotide (NAD)+-
dependent protein deacetylases. SIRs regulate gene silencing,
DNA repair, rDNA recombination, and ageing, apart from
regulating programmed cell death [35]. Furthermore, it
has been demonstrated that neurons in neurodegenerative
disease are rescued by the overexpression of Sirt1, induced
by either calorie restriction or administration of resveratrol
[36, 37]. To characterize potential mechanisms involved in
the senescence preventive activity of EGCG, the expression
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Figure 2: SABG expression (a) of serially passaged HDFs in the absence or presence of 50 and 100 μM EGCG. The quantitative result (b)
showed that the HDFs at early passage (PN 5) that were not treated with EGCG did not stain blue, but the cells at late passage (PN 30 or
≥40) showed much blue staining of senescent cells. Serial passage-induced senescence in HDFs was partly prevented at 50 μM EGCG, while
100 μMEGCG treatment significantly reduced the number of senescent cells. All variables were tested in three independent cultures for each
experiment, which was repeated twice independently (n = 6). The results are reported as a mean± SD and analyzed by a Tukey HSD test.
∗P < 0.05 versus nontreated cells of 5 PN; #P < 0.05 versus nontreated cells of 30 or ≥40 PN.
levels of such proteins as Sirt1, acetylated p53, and p53 in
HDFs after serial passage in the absence or presence of EGCG
were examined by western blot analysis (Figure 3). The
Sirt1 expression slightly decreased as the PN increased up to
30, whereas EGCG maintained its expression level to some
extent even after 30 passages. On the contrary, the expression
levels of acetylated p53 and p53 were remarkably enhanced
after serial passage to 30, while they dramatically decreased
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Figure 3: Eﬀects of EGCG on Sirt1, acetylated p53, and p53 expression in serially passaged HDFs. After treatment with 100 μM EGCG,
the expression levels of Sirt1, acetylated p53, and p53 (a) were determined by western blotting as described in Section 2. Results from
representative experiments were normalized to GAPDH expression by densitometry. The quantitative result (b) is shown below. All variables
were tested in three independent cultures for each experiment, which was repeated twice independently (n = 6). The results are reported as
a mean± SD and analyzed by a Tukey HSD test. ∗P < 0.05 versus nontreated cells of 5 PN; #P < 0.05 versus nontreated cells of 30 PN.
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Figure 4: Eﬀects of EGCG on Sirt1, acetylated p53, and p21 expression in H2O2-treated HDFs. After treatment with 100 μM EGCG,
the expression levels of Sirt1, acetylated p53, and p21 (a) were determined by western blotting as described in Section 2. Results from
representative experiments were normalized to GAPDH expression by densitometry. The quantitative result (b) is shown below. All variables
were tested in three independent cultures for each experiment, which was repeated twice independently (n = 6). The results are reported as
a mean± SD and analyzed by a Tukey HSD test. ∗P < 0.05 versus nontreated cells of 5 PN; #P < 0.05 versus nontreated cells of 30 PN.
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Figure 5: Fluorescence microscopic photographs of proliferating (PN 5) (a) and senescent (PN 30) (b) HDFs treated with 100 μM FITC-
EGCG for 8 h. The micrographs (magnification, ×250) shown in this figure are obtained with a fluorescence microscope and representative
of six independent experiments with similar results. The asterisks in (a) and sharps in (b) indicate the cell nucleus. All photographs (original
magnification, ×250) shown in this figure are representative of six independent experiments with similar results.
by EGCG treatment. We could get some meaningful results
for the suppressive eﬀects of EGCG on the acetylated p53
expression in serially passaged RVSMCs like HDFs, but
not in HACs (data not shown). These findings might be
partly explained by the fact that HACs were the most
sensitive to EGCG among the primary cells employed in
this study (Table 1). Generally, articular chondrocytes exhibit
an age-related decline in proliferative and synthetic capacity
while maintaining the ability to produce proinflammatory
mediators and matrix degrading enzymes [38]. Although
the replicative senescence with serial passage in HACs con-
tributes to the propensity to lose their ability to divide, their
function may begin to deteriorate before they reach cell cycle
arrest, which includes abnormal protein synthesis, altered
growth factor responses, and longer population doubling
times [39].
These results were compared with the eﬀects of EGCG
on alterations in expression of Sirt1, acetylated p53, and
p21 in HDFs treated with 150 μM H2O2 (Figure 4). Some
reports have already revealed that H2O2 treatment induces
the cellular senescence by changing the intracellular ROS
[40, 41]. The expression of Sirt1 was little changed in spite of
H2O2 treatment. However, the expression of acetylated p53
and p21, which is a transcriptional target of p53, significantly
(P < 0.05) increased by H2O2 treatment. H2O2 was shown to
accelerate cellular senescence by accumulation of acetylated
p53 via decrease in the function of sirt1 by NAD+ depletion
[35]. On the other hand, H2O2-induced p53 acetylation
and p21 expression decreased by EGCG treatment. It was
reported that the expression of p16, p21, p27, and p53 in
primary cells treated with antiaging agents such as kinetin
and selenium was significantly reduced [25]. It is considered
that Sirt1 might allow the repair of oxidative stress-induced
damage to the intracellular proteins [42]. This possibility
is explained partly by the fact that EGCG could partially
maintain the activity of Sirt1 and concomitantly stimulate
p53 acetylation.
3.5. Diﬀerential Incorporation Pattern of FITC-EGCG into
Proliferating versus Senescent HDFs. To compare the inter-
nalization of EGCG into the cytoplasm and its further
nuclear translocation in proliferating (PN 5) HDFs with
those of their senescent (PN 30) counterparts, fluorescence
microscopy was performed in both cells treated with 100 μM
FITC-EGCG. Although the cellular response to FITC-EGCG
and its binding pattern to membrane receptors would be
diﬀerent from those of EGCG, FITC-EGCG was seen mainly
at the cytoplasm of the proliferating cells, but not at the
nucleus after 8 h of treatment (Figure 5(a)). In contrast,
FITC-EGCG was entirely distributed inside the senescent
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Figure 6: Diﬀerential cellular uptake of FITC-EGCG in proliferating (PN 5) (a) versus senescent (PN 30) (b) HDFs. Cells were incubated
with 100 μM FITC-EGCG for 8 h and then observed under a confocal laser scanning microscope. The micrographs shown in this figure
are representative of six independent experiments, showing similar results (original magnification: ×500 and ×2000 ((a) and (b), resp.,)).
Arrows in this figure indicate endosome-like structures, where FITC-EGCG was bound for translocation into the nucleus.
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cells including the cytoplasm and nucleus (Figure 5(b)). This
incorporation pattern of FITC-EGCG into the senescent cells
was almost similar to that of L-929 fibroblastic cell line [23].
These results were more confirmed by confocal
microscopy performed under the same conditions as
fluorescence microscopy. FITC-EGCG was observed to
be adsorbed onto the membrane and incorporated in the
cytoplasm of the proliferating HDFs, particularly with
intense bright green fluorescence (Figure 6(a)). At higher
magnification, FITC-EGCG was clearly found to be partially
translocated into the nucleus, bound to endosome-like
structures. This nuclear translocation pattern of FITC-
EGCG in the proliferating cells was completely diﬀerent
from that in the senescent cells, which is considered as an
important contributor to the diﬀerential responses to EGCG
in proliferating versus senescent cells. Confocal micrographs
of the senescent cells showed that FITC-EGCG was widely
distributed into the cytoplasm and the nucleus (Figure 6(b)).
Moreover, the senescent cells were subjected to the nuclear
translocation of FITC-EGCG comparable to normal cells
experiencing apoptosis [21] and human fibrosarcoma
(HT-1080) cells (as the cancer counterparts of HDFs) [31].
Although the exact mechanism of the incorporation of
EGCG into the cells has not been fully elucidated yet, some
evidence has demonstrated that EGCG can be bound to
the membrane and internalized into the cytoplasm and
nucleus of cancer cells such as PC-9 and HT-29 cells treated
with [3H]EGCG [43, 44]. These quantitative results using
[3H]EGCG agree well with our qualitative results showing
that the FITC-EGCG was incorporated into the cytoplasm
of the proliferating cells and their senescent counterparts.
However, the nuclear translocation pattern of FITC-EGCG
in the proliferating cells was completely diﬀerent from
that in the senescent cells. Another study has revealed that
expression of the metastasis-associated 67 kDa laminin
receptor might confer EGCG responsiveness to cancer cells,
suggesting that the gallate moiety of EGCG may be critical
for receptor binding and subsequent activity [45]. These
results imply that FITC-EGCG can be incorporated into the
cytoplasm of the cells, irrespective of the proliferating and
senescent, through binding to specific receptors and forming
complexes with them, whereas it may be diﬀerentially
translocated into the nucleus in the proliferating versus the
senescent cells.
In conclusion, we found that EGCG at 100 μM, which
might be diﬃcult to achieve through diet, could prevent
serial passage- and H2O2-induced senescence in HDFs
via significantly suppressing the p53 acetylation without
aﬀecting the Sirt1 activity as well as showing the diﬀerential
cellular response to EGCG and uptake pattern of EGCG in
proliferating versus senescent HDFs. From these results, it
is suggested that EGCG may be exploited to craft strategies
for the development of an antiaging or age-delaying agent.
Although the concentrations of EGCG remained in the
plasma after oral and intraperitoneal treatments may be
much lower than those used here [46], such preventive eﬀects
of EGCG against cellular senescence can occur at relatively
higher levels. Thus, directions for future research include
investigations of the physiological relevance of the findings
in relationship to the normal consumption of green tea, the
pharmacokinetics and roles of EGCG metabolites, and the
potential synergisms of EGCG with other antioxidants or
drugs.
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